{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:04:40Z","timestamp":1785416680252,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.04.022","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:32:43Z","timestamp":1776468763000},"page":"984.e1-984.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Low-Dose Olanzapine for the Prevention of Conditioning Therapy-Induced Nausea and Vomiting in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8508-7080","authenticated-orcid":false,"given":"Kanae","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimimori","family":"Kamijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Muroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2026.04.022_bib0001","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s44228-022-00012-8","article-title":"Antiemetic strategies in patients who undergo hematopoietic stem cell transplantation","volume":"4","author":"Yuda","year":"2022","journal-title":"Clin Hematol Int"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.022_bib0002","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/bmt.2008.257","article-title":"Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens","volume":"42","author":"Trigg","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2026.04.022_bib0003","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.022_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.022_bib0005","article-title":"2020 ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients","volume":"32","author":"Kennedy","year":"2024","journal-title":"Support Care Cancer"},{"issue":"24","key":"10.1016\/j.jtct.2026.04.022_bib0006","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.022_bib0007","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2025. 2025. Available at: https:\/\/www.nccn.org. Accessed March 25, 2026."},{"issue":"10","key":"10.1016\/j.jtct.2026.04.022_bib0008","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.bbmt.2018.06.005","volume":"24","author":"Clemmons","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.04.022_bib0009","unstructured":"U.S. Department of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed May 18, 2026."},{"key":"10.1016\/j.jtct.2026.04.022_bib0010","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1182\/blood.V96.13.4096","article-title":"Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program","volume":"96","author":"Davies","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.04.022_bib0011","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/bmt.2012.249","article-title":"Effects of spleen status on early outcomes after hematopoietic cell transplantation","volume":"48","author":"Akpek","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.04.022_bib0012","first-page":"250","article-title":"Chronic graft-versus-host disease and other late complications of bone marrow transplantation","volume":"28","author":"Sullivan","year":"1991","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtct.2026.04.022_bib0013","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.022_bib0014","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.022_bib0015","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.022_bib0016","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.04.022_bib0017","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","article-title":"A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"54","author":"Clemons","year":"2020","journal-title":"Breast"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.022_bib0018","first-page":"5335","article-title":"Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus Dex for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy","volume":"28","author":"Ithimakin","year":"2020","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.022_bib0019","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.31557\/APJCP.2022.23.6.2137","article-title":"Efficacy of olanzapine 5 mg versus 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting in patients receiving high emetic risk chemotherapy without neurokinin-1 receptor antagonist","volume":"23","author":"Sukauichai","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jtct.2026.04.022_bib0020","article-title":"Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults","volume":"9","author":"Sutherland","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.022_bib0021","first-page":"356","article-title":"Olanzapine enhances the effect of conventional drugs in chemotherapy inducing nausea and vomiting: a randomized clinical trial","volume":"13","author":"Khani","year":"2022","journal-title":"Caspian J Intern Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.022_bib0022","first-page":"37","article-title":"Olanzapine versus fosaprepitant for chemotherapy-induced nausea and vomiting prophylaxis in patients receiving single-day high-dose melphalan","volume":"11","author":"Ekinci","year":"2021","journal-title":"J Hematol Oncol Pharm"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.022_bib0023","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.clml.2017.12.001","article-title":"Chemotherapy-induced nausea and vomiting prophylaxis in high-dose melphalan and autologous stem cell transplantation","volume":"18","author":"Tendas","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"RR-10","key":"10.1016\/j.jtct.2026.04.022_bib0024","first-page":"1","article-title":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jtct.2026.04.022_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5954379","article-title":"A comparison of the efficacy of 5 mg olanzapine and aprepitant in the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting","volume":"2022","author":"Liu","year":"2022","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.022_bib0026","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.022_bib0027","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.022_bib0028","first-page":"6225","article-title":"Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study","volume":"30","author":"Gao","year":"2022","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.022_bib0029","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jjco\/hyu191","article-title":"A double-blind randomized Phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy","volume":"45","author":"Nagashima","year":"2015","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.022_bib0030","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09392-9","article-title":"Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and Dex for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis","volume":"22","author":"Yamamoto","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.022_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10894","article-title":"Efficacy of olanzapine in addition to standard triplet antiemetic therapy for cisplatin-based chemotherapy: a secondary analysis of the J-FORCE randomized clinical trial","volume":"6","author":"Abe","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtct.2026.04.022_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101771","article-title":"A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)","volume":"55","author":"Zhao","year":"2023","journal-title":"EClinicalmedicine"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:35:52Z","timestamp":1785414952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726003088"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Low-Dose Olanzapine for the Prevention of Conditioning Therapy-Induced Nausea and Vomiting in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}